ResMed Enters $450M Accelerated Share Repurchase Agreement

Summary of Filing

On August 31, 2026, ResMed Inc. (NYSE: RMD) entered into an Accelerated Share Repurchase (ASR) Agreement with Citibank, N.A. to repurchase $450.0 million of its Common Stock.

Key Terms & Structure

• Total Repurchase Value: $450.0 million.
• Payment & Initial Delivery: ResMed will make the $450.0 million payment to Citibank on September 3, 2026, receiving an initial share delivery equal to 80% of the $450.0 million divided by the closing price of Common Stock on September 2, 2026.
• Pricing Mechanism: Final share count will be calculated using the volume-weighted average price (VWAP) of the Common Stock during the term of the agreement, less an agreed discount.
• Final Settlement: Scheduled for December 2026 (subject to Citibank's early termination rights).
• Funding Sources: Proceeds from the MatrixCare business divestiture and existing cash on hand.
• Repurchase Authority: Executed under the 20,000,000 share repurchase program authorized by the Board of Directors in February 2014.

Strategic Impact

This transaction executes capital allocation guidance previously provided during ResMed's Q4 FY26 earnings call on August 6, 2026, demonstrating an active return of capital following the divestment of MatrixCare.